LipoCure is developing a number of highly-potent therapeutics utilizing proprietary liposome-based nano-drugs with novel drug-loading-capabilities and drug-release mechanisms.
Inflammatory diseases and cancers are treated with very potent drugs that are often associated with severe side effects. It has been shown that effective passive targeting and drug delivery approaches dramatically improve clinical efficacy and safety of many of these potent drugs. The commonly used anti-cancer Doxil®, one of the gold standards of several anticancer therapies, exemplifies such a case. The superior efficacy of Doxil® is due to the major reduction of severe cardiotoxicity of the highly-potent anticancer drug, doxorubicin. This was achieved by the combination of the liposomal delivery technology, bioenergetics and nano-technology, which when combined allow for the transformation of a small-molecule drug into a superior nano-drug with significantly improved therapeutic index and overall performance.
LipoCure’s founder, Professor Barenholz, the co-developer of Doxil®, has been investigating liposomal drug delivery systems for several decades. LipoCure's unique platform technology is the result of many years of his intensive research efforts to bring the myriad sufferers more effective and safer therapies.
LipoCure’s proprietary platform implements a highly-efficient innovative approach which allows for the remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site. Thus, this unique technology allows for an enhanced permeability and retention (EPR) effect, a significantly improved therapeutic effect and reduced side effects of several well-established drugs widely used for the treatment of rheumatoid arthritis, multiple sclerosis and cancer.